This trial is evaluating whether SAR442085 will improve 3 primary outcomes and 7 secondary outcomes in patients with Plasma Cell Myeloma. Measurement will happen over the course of At the end of Cycle 1 (each cycle is approximately 28 days).
This trial requires 37 total participants across 2 different treatment groups
This trial involves 2 different treatments. SAR442085 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Signs include a gradual onset of bone lesions, a gradual increase in blood levels of calcium and blood products, bone pain, weight loss, and a low serum albumin level. The symptoms differ with the disease progression. The Bence Jones protein level, the degree of paraproteinemia, and the presence or absence of a monoclonal protein are key prognostic factors." - Anonymous Online Contributor
"Around 28,000 people will be diagnosed with multiple myeloma in the United States in 2020. This makes it the fifth most common cancer in that population. The number of new cases of multiple myeloma is expected to rise by 2040. The United States has one of the highest rates of multiple myeloma among developed nations." - Anonymous Online Contributor
"This is a cancer syndrome where a malignant myeloma has made its presence and the bone marrow has created a condition where other types of body cells are no longer able to differentiate and function. It usually affects the elderly but has made its presence in all ages and in all cultures in which people live. It often remains unrecognized till the cancer is too advanced to be treated and the person dies. In the past, cancer therapy and chemotherapy were unknown as treatment options in multiple myeloma. As a result, multiple myeloma was often diagnosed late and had a poor prognosis." - Anonymous Online Contributor
"Almost 75% of patients with MM received treatment at least once, and almost half received more than once. It was common for multiple therapy to be delivered, usually (40%) from the side effects of the initial treatment." - Anonymous Online Contributor
"MM is an incurable disease. Despite aggressive treatment, with an overall five year and ten year survival rate of around 25%, patients will often have a progression of the disease. Patients that have previously undergone a brief course of treatment should not be dissuaded from a curative intention; but patients with long term disease should be informed about a high risk of death." - Anonymous Online Contributor
"There may be differences in the genetic causes of multiple myeloma among Western European immigrants compared with individuals of European ancestry residing in other regions." - Anonymous Online Contributor
"Most patients who were referred for testing did not wish to pursue additional testing. Clinical trial eligibility criteria were not correlated with survival, but they were associated with higher levels of overall satisfaction with care." - Anonymous Online Contributor
"Sar442085 was more effective in patients with myeloma whose disease had progressed and who had received a bortezomib-based consolidation treatment than with sar442085 or placebo." - Anonymous Online Contributor
"Recently, several new, potentially effective, drugs for treating MM were developed. The progress of MM research is accelerating since 2008. These drugs or approaches are mostly under investigation; the final results of their evaluation in the treatment of MM remain to be published." - Anonymous Online Contributor
"Sar442085 is highly effective in relieving symptoms of myeloma. It may be of benefit to people who are intolerant of chemotherapy or whose myeloma has grown worse because of ongoing treatments." - Anonymous Online Contributor
"There is a higher probability of PFS when sar442085 is used in combination with other therapies in patients who are undergoing chemotherapy. Further studies in this patient population with sar442088 are warranted to confirm these preliminary findings. Importantly, patient-reported satisfaction is similar with sar448055 and sar442085." - Anonymous Online Contributor
"Recent findings show that the familial clustering of multiple myeloma, previously only reported among AL amyloidotic families, may be more widespread in families with MM. The association of this disorder with the HLA DRbeta3-DQ2 haplotype suggests that this MM association may be mediated through a disease-associated HLA haplotype in at least some MM families." - Anonymous Online Contributor